Tests rosuvastatin for depression in adults with major depressive disorder
Tests whether rosuvastatin, a cholesterol drug, may help adults with major depression.
Plain-language title generated from the registry record
Registry title: Efficacy of Statins Among Major Depressive Disorder
Key facts
- Where
- Cairo, EgyptSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 45 years old?
Source: NCT06698666, who can take part
Where in Egypt
- El-Demerdash hospitalCairo, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ain Shams University
- Trial code
- NCT06698666
- Record updated
- 4 November 2026
- Original description
The goal of this clinical trial is to learn if drug Rosuvastatin 10 mg works to treat MDD in adults. It will also learn about the safety of Rosuvastatin 10 mg .The main questions it aims to answer are:Read full original descriptionShow less
The Efficacy of Statins in Management of Major Depression Disorder (MDD) Among Adult Patients Attending the Outpatient Clinics of El Demerdash Hospital.
The goal of this clinical trial is to learn if drug Rosuvastatin 10 mg works to treat MDD in adults. It will also learn about the safety of Rosuvastatin 10 mg .The main questions it aims to answer are:
Does Rusovastatin lower the score of The Montgomery Asberg Depression Rating Scale (MADRS) among adult participants with Major Depression Disorder ( MDD )? What medical problems do participants have when taking drug ABC?
Participants will:
Take Rosuvastatin 10 mg every day for 3 months Visit the clinic once every 4 weeks for checkups and tests Report any side effects for Rosuvastatin 10 mg and reassess the severity of depression using The Montgomery Asberg Depression Rating Scale (MADRS)
Inclusion: aged between 20 and 45 years; diagnosis of current MDD, verified using the Structured Clinical Interview for DSM-IV Axis I Disorders, patient version (SCID-I/P); The Montgomery Asberg Depression Rating Scale (MADRS) score of 7 to 34, indicating mild to moderate depression; the ability to give informed consent and to comply with standard procedures; Males and females; and; Stable pharmacological treatment for at least 2 weeks prior to enrolment (changes to medication dose or frequency of therapy excepted) if currently being treated.
Exclusion: Current regular use of statins, corticosteroids, or any other immunomodulatory agents; and; lifetime or current SCID-I/P diagnosis of a psychotic disorder; lifetime SCID-I/P diagnosis of bipolar I or II disorder or alcohol dependence; acute or unstable systemic medical disorder; history of intolerance or allergy to study medications; inability to comply with the requirements of informed consent or the study protocol; Current pregnancy or breast feeding; Females on Contraception.